Oas1c Activators
Oas1c Activators encompass a variety of chemical compounds that enhance the functional activity of Oas1c, a crucial protein in the antiviral response mechanism. Synthetic analogues of double-stranded RNA, such as Poly(I:C) and Polyadenylic-polyuridylic acid, play a significant role in activating Oas1c. These molecules mimic viral RNA, triggering Oas1c to synthesize 2'-5'-oligoadenylates, which in turn activate RNase L, leading to the degradation of viral RNA. This mechanism is central to the body's defense against viral infections. Additionally, cytokines like Interferon-alpha and Interferon-beta directly influence Oas1c activity by inducing the JAK-STAT signaling pathway. This pathway is instrumental in upregulating Oas1c expression, thus enhancing its antiviral function. Other activators such as Resiquimod, Imiquimod, and Gardiquimod, which target toll-like receptors, also contribute to the upregulation of Oas1c. These compounds simulate viral infections, triggering immune responses that elevate Oas1c's role in combating viral RNA.
Furthermore, the role of antiviral drugs like Ribavirin in enhancing Oas1c activity is noteworthy. Ribavirin generates RNA mutations that mimic viral RNA, thereby activating Oas1c's antiviral response. This highlights the intricate relationship between pharmaceutical agents and innate immune mechanisms. Moreover, JAK inhibitors like Ruxolitinib, Tofacitinib, and Baricitinib exhibit a paradoxical effect; while they inhibit JAK signaling, they can also enhance Oas1c activity in certain contexts by modulating the immune response. This suggests a complex interplay between cytokine signaling and Oas1c regulation. Anakinra, an IL-1 receptor antagonist, further illustrates the indirect pathways through which Oas1c activity can be enhanced. By altering the cytokine environment, Anakinra potentially leads to an increased Oas1c-mediated antiviral response. Collectively, these Oas1c activators demonstrate the diverse mechanisms through which chemical compounds can enhance the function of this crucial protein in antiviral defense, underlining the multifaceted nature of immune response modulation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Polyinosinic-polycytidylic acid potassium salt | 31852-29-6 | sc-202767 | 5 mg | $198.00 | ||
Poly(I:C), a synthetic analogue of double-stranded RNA, enhances Oas1c activity by mimicking viral RNA, thereby activating the Oas1c-mediated antiviral response. Upon binding, Oas1c synthesizes 2'-5'-oligoadenylates, which activate RNase L, leading to the degradation of viral RNA. | ||||||
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $102.00 $306.00 $510.00 $1559.00 | 12 | |
Resiquimod, a toll-like receptor 7/8 agonist, enhances Oas1c activity by simulating viral infection, triggering antiviral responses, and thereby upregulating Oas1c-mediated RNA degradation pathways. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Imiquimod, another toll-like receptor 7 agonist, activates immune responses that include upregulation of Oas1c, leading to enhanced RNA degradation in viral defense. | ||||||
Gardiquimod | 1020412-43-4 | sc-221663 sc-221663A sc-221663B sc-221663C sc-221663D sc-221663E sc-221663F | 25 mg 50 mg 100 mg 250 mg 5 g 10 g 25 g | $157.00 $282.00 $516.00 $1177.00 $20138.00 $32779.00 $70753.00 | 1 | |
Gardiquimod, targeting toll-like receptor 7, stimulates the immune response, indirectly enhancing Oas1c activity by promoting its expression and subsequent antiviral action. | ||||||
Ribavirin | 36791-04-5 | sc-203238 sc-203238A sc-203238B | 10 mg 100 mg 5 g | $63.00 $110.00 $214.00 | 1 | |
Ribavirin, an antiviral drug, enhances Oas1c activity indirectly by generating RNA mutations that mimic viral RNA, activating Oas1c's antiviral response and 2'-5'-oligoadenylate synthesis. | ||||||
Polyinosinic acid - polycytidylic acid sodium salt, double-stranded | 42424-50-0 | sc-204854 sc-204854A | 10 mg 100 mg | $139.00 $663.00 | 2 | |
This synthetic double-stranded RNA analogue activates Oas1c by mimicking viral RNA, leading to increased synthesis of 2'-5'-oligoadenylates and activation of RNase L. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib, a JAK inhibitor, paradoxically enhances Oas1c activity in certain contexts by modulating the immune response, potentially increasing Oas1c's role in antiviral defense. | ||||||
Anakinra | 143090-92-0 | sc-507486 | 10 mg | $811.00 | ||
Anakinra, an IL-1 receptor antagonist, may indirectly enhance Oas1c activity by modulating the cytokine environment, potentially leading to an increased Oas1c-mediated antiviral response. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $200.00 $664.00 | ||
Baricitinib, another JAK inhibitor, can indirectly enhance Oas1c activity by altering immune signaling pathways, potentially leading to increased expression of Oas1c in certain conditions. | ||||||